SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

DAYBUE

ACAD·ACADIA PHARMACEUTICALS INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed in the US (since March 2023) and EU (since August 2026). Japan regulatory filing planned for 2027 with potential launch in 2028.
Why 4/10
DAYBUE is already FDA-approved (March 2023) and EU-approved (August 2026) with no pending regulatory decision. The next catalyst is a Japan regulatory filing planned for 2027, which is more than 12 months out. As an approved, commercial-stage drug with no hard dated binary catalyst in the next ~12 months, the impact score is capped at 4 per the rubric.
Actionable Insight NEUTRAL

DAYBUE is already approved and generating strong commercial revenue. The next catalyst for this specific drug is the planned Japan regulatory filing in 2027, which could support a 2028 launch, but no hard date is set. Watch quarterly DAYBUE sales growth trajectory and European launch uptake (Germany launched October 2026) as the key near-term value drivers for ACAD stock.

Price Chart

Loading chart...

Executive Summary

DAYBUE (trofinetide) is Acadia Pharmaceuticals' approved treatment for Rett syndrome, a rare genetic neurological disorder. FDA-approved in March 2023 as the first and only treatment for the condition, it was also approved by the European Commission in August 2026. The drug generated strong Q3 2026 sales (up 39% YoY), leading Acadia to raise full-year guidance to $505-$520 million. A new powder formulation (DAYBUE STIX) launched in 2026, and patent protection was extended to 2041. A Phase 3 Japan study completed with positive results, supporting a planned 2027 regulatory filing. With no pending binary regulatory catalyst, DAYBUE is a mature commercial asset driving Acadia's revenue alongside NUPLAZID.

How It Works

Trofinetide is a synthetic version of a small protein fragment (GPE) that occurs naturally at the tip of IGF-1, a growth factor important for brain development. In Rett syndrome, IGF-1 levels in the brain are lower than normal, which is thought to impair nerve cell function. Trofinetide is designed to compensate for this deficiency by supporting neuronal connections and reducing inflammation in the brain. It is taken by mouth as a liquid or powder solution.

Trial Status

DAYBUE was approved by the FDA in March 2023 based on the Phase 3 LAVENDER study (NCT04181723), a 12-week randomized, double-blind, placebo-controlled trial in patients aged 5-20. The Phase 3 Japan study has been completed with results consistent with LAVENDER, supporting a planned regulatory filing in 2027. Real-world effectiveness studies continue to publish positive data.

The Two-Sided Case

▲ Bull Case8
DAYBUE is the first and only FDA-approved treatment for Rett syndrome, a rare neurodevelopmental disorder with no direct approved competitors, giving it a market monopoly.
Q3 2026 DAYBUE net sales surged 39% year-over-year, leading ACAD to raise full-year 2026 guidance to $505-$520 million.
European Commission approved DAYBU (trofinetide) on August 24, 2026, opening a new geographic market; Germany launched in October 2026.
Patent protection extended to March 2041 via a new USPTO allowance covering weight-banded dosing, providing long-term exclusivity.
DAYBUE STIX (powder formulation) launched in 2026 addresses formulation challenges (taste, dosing volume, refrigeration) and could expand the addressable patient population.
Analyst consensus is bullish: 20 Buy/Strong Buy ratings vs 6 Hold and 1 Sell, with a mean price target of $30.53, implying ~44% upside from the current $21.23 price.
Phase 3 Japan study completed with positive results consistent with the pivotal LAVENDER study, supporting a planned 2027 regulatory filing and potential 2028 launch.
Expert consensus now recognizes trofinetide as part of the standard of care for Rett syndrome, supporting continued adoption.
▼ Bear Case6
UBS downgraded ACAD from Buy to Neutral in October 2026, reflecting concerns about growth trajectory or valuation.
CFO Mark Schneyer sold $69,342 worth of shares on October 30, 2026 at $20.88, a bearish insider signal.
The EMA initially refused marketing authorization for Daybu in February 2026 before granting a restricted indication after re-examination, highlighting regulatory risk in new markets.
Gastrointestinal side effects (diarrhea, vomiting) are common with trofinetide and may limit patient adherence and market penetration.
Multiple institutional investors trimmed or exited ACAD positions in Q2/Q3 2026, including First Trust, Jane Street, and T. Rowe Price (trim, -67.4%).
ACAD stock trades near the low end of its 52-week range ($18.39-$30.96) at ~$21.23, suggesting market skepticism about growth sustainability.

Upcoming Catalysts

  • Japan regulatory filing for trofinetide planned for 2027 (potential launch 2028)
  • European commercial launch rollout across additional EU countries following Germany launch in October 2026
  • Quarterly DAYBUE sales reports as key commercial performance indicators

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ACADIA PHARMACEUTICALS INC 8-K ACAD ·Originating report

Sources · 11

Hover a chip for the title
1 fda.gov2 biospace.com3 ir.acadia.com4 businesswire.com5 morningstar.com6 investing.com7 ema.europa.eu8 sec.gov9 listcorp.com10 rettsyndromenews.com11 acadia.com